Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
What adjuvant therapy, if any, would you offer for a young fit patient with stage IB lung adenocarcinoma harboring an EGFR A763_Y764insFQEA who received no prior therapy?
Related Questions
How do you schedule IV/PO Dexamethasone if giving immunotherapy concurrently with chemotherapy in patients with NSCLC?
Would you consider ALK-directed TKI for a ALK L1198F point mutation in a patient with metastatic lung adenocarcinoma after progressing through first line chemoimmunotherapy?
Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?
Which targeted therapies should we be more cautious of giving after recent immunotherapy in NSCLC?
How are you approaching patients who receive neoadjuvant chemo immunotherapy for resectable NSCLC who after completion of neoadjuvant treatment are no longer surgical candidates due to factors such as toxicity, decline in PS, or patient preference?
Would you consider Amivantamab + Lazertinib combo for first line in EGFR mutated metastatic NSCLC, given the recent ESMO updates?
When do you offer SBRT for a small, slowly growing lung lesion?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
For patients with biphasic mesothelioma who complete pleurectomy/decortication, would you consider offering adjuvant combination immune checkpoint inhibitor therapy vs. platinum chemotherapy?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?